- Home
- GATX vs RYTM Comparison
GATX vs RYTM Comparison
Compare GATX & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GATX | RYTM |
|---|---|---|
| Founded | 1898 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.4B |
| IPO Year | 1994 | 2017 |
Fundamental Metrics
Financial Performance| Metric | GATX | RYTM |
|---|---|---|
| Price | $174.78 | $93.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | ★ $215.00 | $129.43 |
| AVG Volume (30 Days) | 181.4K | ★ 739.0K |
| Earning Date | 05-22-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | 17.22 | ★ 28.34 |
| EPS | ★ 9.12 | N/A |
| Revenue | ★ $1,740,400,000.00 | N/A |
| Revenue This Year | $42.09 | $58.38 |
| Revenue Next Year | $3.32 | $83.95 |
| P/E Ratio | $19.55 | ★ N/A |
| Revenue Growth | ★ 9.77 | N/A |
| 52 Week Low | $139.44 | $45.91 |
| 52 Week High | $199.00 | $122.20 |
Technical Indicators
Market Signals| Indicator | GATX | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 33.53 | 43.04 |
| Support Level | $168.23 | $85.59 |
| Resistance Level | $176.55 | $96.92 |
| Average True Range (ATR) | 5.31 | 4.80 |
| MACD | -2.12 | -0.31 |
| Stochastic Oscillator | 0.39 | 37.00 |
Price Performance
Historical ComparisonAbout GATX GATX Corporation
GATX Corp is a provider of railcar leasing and maintenance services. GATX operates in business segments including rail North America, rail international, Engine Leasing, and others. The rail business offers railcar leasing and maintenance, as well as asset-related, financial, and management services. The company owns and leases fleets in North America, Europe, and Asia, which consist of tank and freight railcars. Industries served include refining and petroleum, chemicals and plastics, railroads and other transportation, mining, and food and agriculture.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.